Tiger Aesthetics Medical, LLC, a division of Tiger Biosciences, announced a strategic investment in GenesisTissue Inc, an early-stage biotechnology company transforming breast reconstruction and cosmetic surgery through advanced personalized 3D bioprinting.
This investment underscores Tiger’s vision of creating new and disruptive innovation for breast reconstruction and augmentation through tissue engineering and regenerative technologies, first demonstrated with the launch of alloClae in 2025. alloClae is Tiger’s groundbreaking, ready-to-use structural adipose tissue product uniquely designed for body contouring.
“Tiger Aesthetics was founded on the belief that tissue engineering & regenerative therapies will be the future of medical aesthetics. This year’s launch of alloClae underscores our commitment to creating advanced treatment options that naturally integrate with one’s body,” said Caro Van Hove, President of Tiger Aesthetics. “GenesisTissue shares our vision, and alongside alloClae, its 3D bioprinted scaffold represents the kind of bold innovation that will shape a new paradigm for plastic and reconstructive surgery.”
With disruptive regenerative tissue products like alloClae, a best-in-class portfolio of breast implants, expanders, and fat grafting technologies, Tiger is now expanding its innovation pipeline through partnerships that will shape the future of breast surgery.
Built on one of the most advanced 3D bioprinting platforms in the industry, GenesisTissue integrates personalized planning, advanced material science, and precision tissue engineering. The company is developing solutions for both lumpectomy and mastectomy reconstruction, as well as cosmetic applications.
Each year, more than 2 million women are diagnosed with breast cancer worldwide. With limited choices outside of implant-based surgery, nearly 200,000 women in the U.S. alone undergo a mastectomy or lumpectomy and forego breast reconstruction. This issue is particularly prevalent for those that undergo lumpectomy, a growing procedure for which there is not currently an implant-based option, leaving many patients with significant asymmetry or volume loss.
GenesisTissue’s flagship innovation is a degradable, bioprinted scaffold personalized for each patient to provide mechanical support for autologous or allogeneic fat transfer as a potential alternative to silicone gel breast implants. Over time, the scaffold is designed to be naturally replaced by the patient’s own tissue, with a goal of enabling a 100% natural breast reconstruction or augmentation.
Katie Weimer, CEO and co-founder at GenesisTissue, stated, “At GenesisTissue, we see a future where technology and biology come together to restore confidence, form, and function. With advances in 3D bioprinting and material science, we can finally move beyond implants made from legacy industrial materials toward living, regenerative solutions. Every woman deserves the right to a lifelong, natural breast restoration. This is what drives our team every day.”
